ANI Pharmaceuticals (ANIP) CEO logs restricted stock grant and tax-withholding share disposition

Rhea-AI Filing Summary

ANI Pharmaceuticals President and CEO Nikhil Lalwani reported two equity compensation events involving the company’s common stock. On February 26, 2026, he acquired 75,592 shares through a restricted stock award at $77.15 per share. According to the footnotes, this award will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026, tying his compensation to multi‑year performance.

On February 28, 2026, Lalwani had 12,217 shares withheld at $73.90 per share as a tax-withholding disposition in connection with the vesting of 23,883 previously granted restricted shares. These shares were withheld for tax purposes and are exempt under Rule 16(b)-3, rather than being an open-market sale. After these transactions, his directly owned common stock holdings were reported at 434,166 shares following the award and 421,949 shares following the tax withholding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalwani Nikhil

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		75,592	A	$77.15	434,166	D
Common Stock	02/28/2026		F(2)		12,217	D	$73.9	421,949	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,883 shares of restricted stock, the grant of which was previously reported.

Remarks:

	/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ANIP CEO Nikhil Lalwani report on this Form 4?

Nikhil Lalwani reported a restricted stock award of 75,592 ANI Pharmaceuticals common shares and a separate tax-withholding disposition of 12,217 shares tied to vesting of previously granted restricted stock, all held directly in his name as equity compensation events.

How many ANI Pharmaceuticals (ANIP) shares were granted to the CEO and at what price?

The CEO received a grant of 75,592 shares of ANI Pharmaceuticals common stock at a reported value of $77.15 per share. This was characterized as a restricted stock award, not an open-market purchase, and increases his direct equity-based compensation exposure to the company.

What is the vesting schedule for the 75,592 restricted ANI Pharmaceuticals shares?

The 75,592 restricted shares will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026. This structure encourages longer-term alignment, as full vesting occurs over four years, contingent on continued service and any plan conditions.

Why were 12,217 ANI Pharmaceuticals shares disposed of by the CEO?

The 12,217 shares were withheld solely for tax purposes in connection with the vesting of 23,883 previously granted restricted shares. This tax-withholding disposition, reported at $73.90 per share, is exempt under Rule 16(b)-3 and does not represent an open-market sale transaction.

How many ANI Pharmaceuticals (ANIP) shares does the CEO hold after these transactions?

After reporting the restricted stock award and tax-withholding disposition, the CEO’s direct holdings were listed as 434,166 shares following the grant and 421,949 shares following the tax withholding. These figures reflect his updated direct ownership of ANI Pharmaceuticals common stock as reported.

Are the ANI Pharmaceuticals CEO’s reported transactions open-market buys or sells?

Neither transaction is an open-market buy or sell. One is a grant of 75,592 restricted shares as compensation, and the other is a 12,217-share tax-withholding disposition tied to vesting, exempt under Rule 16(b)-3, rather than discretionary trading in the open market.